Zydus receives tentative approval from the USFDA for Bosentan Tablets for Oral Suspension

Zydus Lifesciences has announced that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Bosentan Tablets for Oral Suspension, 32 mg, via an exchnage filing.

Bosentan Tablet for oral suspension is indicated for the treatment of pulmonary arterial hypertension (PAH) in pediatric patients aged 3 years and older with idiopathic or congenial PAH to improve pulmonary vascular resistance (PVR).

The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

Bosentan Tablets for Oral Suspension had annual sales of USD 16 mn in the United States (IQVIA MAT Dec. 2022).

FPJ Shorts

'Saddened To Support A Regime Failing To Curb Crime': Chirag Paswan Slams Nitish Kumar Govt Ahead Of Bihar 2025 Polls (Video)

Thane Police Recover 105 Missing Mobile Phones Worth ₹31.5 Lakh Across 4 Stations, Return Devices To Owners

'Might Need Oxygen If I...': Karan Johar Says Meryl Streep & Anne Hathaway's The Devil Wears Prada 2 BTS Clips Are Driving Him 'Crazy'

War 2 Cast Fees: ₹ 50 Crore Plus Profit Sharing For Hrithik Roshan, Jr NTR Paid ₹ 70 Crore; Most Expensive YRF Spy Universe Film (Report)

The group now has 341 approvals and has so far filed over 440 ANDAs since th commencement of the filing process in FY 2003-04.

Read Also

Zydus receives tentative approval from the USFDA for Canagliflozin Tablets